Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.73 |
| ▸ | POLB | P06746 | 2/20 | 0.73 |
| ▸ | CDC25B | P30305 | 2/20 | 0.68 |
| ▸ | CDC25A | P30304 | 1/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.68 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.66 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.62 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31364358 | 1.00 | ALDH1A1 (0.73) | ALDH1A1POLBCDC25BCDC25AHSD17B10 | |
| SCHEMBL10727775 | 0.85 | SLC6A2 (0.60) | ALDH1A1POLBCDC25BCDC25AHSD17B10 | |
| SCHEMBL30912248 | 0.85 | ALDH1A1 (0.77) | ALDH1A1POLBCDC25BCDC25AHSD17B10 | |
| SCHEMBL11550449 | 0.85 | ALDH1A1 (0.73) | ALDH1A1POLBCDC25BCDC25AHSD17B10 | |
| SCHEMBL614963 | 0.85 | ALDH1A1 (0.77) | ALDH1A1POLBCDC25BCDC25AHSD17B10 | |
| SCHEMBL24703953 | 0.83 | NR4A1 (0.58) | ALDH1A1POLBCDC25BCDC25AHSD17B10 | |
| SCHEMBL31310077 | 0.81 | ALDH1A1 (0.58) | ALDH1A1POLBCDC25BCDC25AHSD17B10 | |
| SCHEMBL10442862 | 0.81 | ALDH1A1 (0.58) | ALDH1A1POLBCDC25BCDC25AHSD17B10 | |
| SCHEMBL29736650 | 0.81 | ALDH1A1 (0.58) | ALDH1A1POLBCDC25BCDC25AHSD17B10 | |
| SCHEMBL19334467 | 0.81 | POLB (0.58) | ALDH1A1POLBCDC25BCDC25AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9650362-B2 | Inhibitors | PROBIODRUG AG (DE) | 2017-05-16 | — | — | US | disclosed |
| US-20160039795-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2016-02-11 | — | — | US | disclosed |
| US-9173885-B2 | Inhibitors | PROBIODRUG AG (DE) | 2015-11-03 | — | — | US | disclosed |
| EP-2475428-B1 | HETEROCYLCIC DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2015-07-01 | — | — | EP | disclosed |
| US-20140065095-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2014-03-06 | — | — | US | disclosed |
| US-8486940-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-07-16 | — | — | US | disclosed |
| EP-2475428-A1 | HETEROCYLCIC DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2012-07-18 | — | — | EP | disclosed |
| US-20110092501-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-04-21 | — | — | US | disclosed |
| WO-2011029920-A1 | HETEROCYLCIC DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2011-03-17 | — | — | WO | disclosed |
| US-20090253908-A1 | NOVEL M3 MUSCARINIC ACETYLCHOINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED | 2009-10-08 | — | — | US | disclosed |
| WO-2005087236-A1 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-09-22 | — | — | WO | disclosed |
| US-5624922-A | Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC. (US) | 1997-04-29 | — | — | US | disclosed |
| EP-0597540-B1 | Aryl-fused and hetaryl-fused-2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC (US) | 1996-06-05 | — | — | EP | disclosed |
| US-5380721-A | Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC. (US) | 1995-01-10 | — | — | US | disclosed |
| EP-0597540-A1 | Aryl-fused and hetaryl-fused-2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC. (US) | 1994-05-18 | — | — | EP | disclosed |
| US-4322356-A | Method of preparing substituted phthalides | THE DOW CHEMICAL CO. (US) | 1982-03-30 | — | — | US | disclosed |
| US-4188330-A | Substituted phthalide derivatives | THE DOW CHEMICAL COMPANY (US) | 1980-02-12 | — | — | US | disclosed |
| US-4058529-A | Polycyclic amino derivatives of pyrrolidone and piperidone | CIBA-GEIGY CORPORATION (US) | 1977-11-15 | — | — | US | disclosed |
| US-4036855-A | Phthalides and process for preparing same | SANDOZ, INC. (US) | 1977-07-19 | — | — | US | disclosed |
| US-3943147-A | Process for imidazo isoindoles | SANDOZ, INC. (US) | 1976-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092501-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | ALDH1A1 2195/4885POLB 1125/4885CDC25B 953/4885 |
| US-20160039795-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | ALDH1A1 2195/4885POLB 1125/4885CDC25B 953/4885 |
| US-20140065095-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | ALDH1A1 2195/4885POLB 1125/4885CDC25B 953/4885 |
| US-20090253908-A1 | NOVEL M3 MUSCARINIC ACETYLCHOINE RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRNA3 | ALDH1A1 1423/4885POLB 4388/4885CDC25B 4530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.